No profile data available.
argenx SE (ARGX) is a healthcare company in the brain and nerve treatment drugs industry, based in Amsterdam, Netherlands, with about 1,863 full-time employees.
It reported revenue of $4.15 billion for fiscal year 2025, up 89.6% from fiscal year 2024, and net income of $1.29 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.52 billion, up 59.8% from a year before. United States was its largest region in fiscal year 2025, with 85% of revenue. Its market capitalization was $51.88 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
argenx reported $4.15 billion in revenue for fiscal year 2025, up 89.6% from $2.19 billion in fiscal year 2024. In Q2 2026 revenue was $1.52 billion.
United States: 85% of revenue by region in fiscal year 2025, followed by Rest of The World (8%).
$51.88 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Biogen Inc. (BIIB), Neurocrine Biosciences, Inc. (NBIX), Jazz Pharmaceuticals plc (JAZZ), Axsome Therapeutics, Inc. (AXSM).